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Background: The active human mobile element, long interspersed element 1 (L1) currently populates human
genomes in excess of 500,000 copies per haploid genome. Through its mobility via a process called target primed
reverse transcription (TPRT), L1 mobilization has resulted in over 100 de novo cases of human disease and has recently
been associated with various cancer types. Large advances in high-throughput sequencing (HTS) technology have
allowed for an increased understanding of the role of L1 in human cancer; however, researchers are still limited by the
ability to validate potentially rare L1 insertion events detected by HTS that may occur in only a small fraction of tumor
cells. Additionally, HTS detection of rare events varies greatly as a function of read depth, and new tools for de novo
element discovery are needed to fill in gaps created by HTS.
Results: We have employed droplet digital PCR (ddPCR) to detect rare L1 loci in mosaic human genomes. Our assay
allows for the detection of L1 insertions as rare as one cell in every 10,000.
Conclusions: ddPCR represents a robust method to be used alongside HTS techniques for detecting, validating and
quantitating rare L1 insertion events in tumors and other tissues.
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The human retrotransposon, long interspersed element
1 (L1) exists in over half a million copies per genome
and constitutes 17% of genomic content [1]. The major-
ity of these copies are nonfunctional relics that litter the
genome; however, on average, approximately 100 L1 ele-
ments remain active in any given individual [1,2]. These
active L1 elements mobilize in both germline and som-
atic tissues [3-11]. De novo L1 retrotransposition has
been responsible for numerous germline diseases, as well
as being implicated in tumorigenesis [8,10,12]. Notably,
de novo L1 insertions have been identified in numerous
cancer types including lung, colon, prostate, ovarian, and
hepatocellular carcinoma through the use of high-
throughput sequencing (HTS) technology [3-11].
Because tumors are often heterogeneous in genomic
content, discovery and validation of de novo L1 insertion
events detected by HTS in tumors can be problematic
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unless otherwise stated.somatic insertions have been reported to be as low as
67% [11]. One explanation for this fairly low rate of val-
idation is tumor heterogeneity. Somatic L1 insertion
events that occur late in tumorigenesis may represent a
small minority of cells, and even insertion events that
occur early in tumorigenesis may not be present in all
tissue derived from that tumor. Some studies have had
significantly higher validations, [3,7,10] but as methods
develop to detect insertions present in smaller propor-
tions of tumor cells, we can expect validation to become
progressively more difficult.
Droplet digital PCR (ddPCR) has recently emerged as a
robust tool to provide precise measurements of nucleic
acid target concentrations [14,15]. In ddPCR, input DNA
is partitioned, along with PCR reagents, into approxi-
mately 20,000 droplets as a water-in-oil emulsion within a
single thermocycled reaction well [16]. Detection of target
DNA relies on fluorogenic probes in a 5’-nuclease assay
(TaqMan™) [17,18]. Briefly, an oligonucleotide probe,
which anneals specifically to a target DNA within the pri-
mer binding sites, is included in the PCR with the primers.
The probe is modified at the 5’ end with a fluorescent
moiety, which is quenched in the intact probe by aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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probe anneals to the target DNA during the annealing/ex-
tension step of the PCR. During extension of the primer
that anneals to the same DNA strand as the probe, the 5’
to 3’ nuclease activity of Taq polymerase cleaves the probe,
which separates the 5’-fluorescent nucleotide of the probe
from the 3’ quencher, generating a fluorescent signal.
Sequestration of template DNA occurs in ddPCR, such
that some droplets contain no copies and others one or
more copies of the template target DNA [14,16]. Identi-
fication of template target DNA-containing droplets is
achieved through fluorescence analysis of the droplets
according to the 5’-fluorogenic probes used in the
ddPCR. Droplets containing one or more target tem-
plates generate increased fluorescence compared to
droplets containing non-target DNA. Thus, the quantifi-
cation comes from the ability to essentially detect a sin-
gle DNA template sequestered into a droplet through
PCR amplification of the templates followed by counting
of fluorescent droplets. The concentration of the input
target DNA is calculated according to a Poisson distribu-
tion of template DNA molecules partitioned into the fluor-
escence-positive droplets [16]. Recent reports use ddPCR
to successfully identify very rare alleles (that is, <1%) in
heterogeneous tumor samples, making ddPCR an ideal
method to apply for detection of rare de novo L1 insertion
events [16]. Additionally, the utility of ddPCR over trad-
itional qPCR methods has recently been examined [19].
Due to the high copy number of L1 sequence in the
human genome, detection of specific polymorphic loci
in a heterogeneous sample by traditional qPCR ap-
proaches is particularly difficult due to the high back-
ground signal created from nonspecific amplification
from templates that do not contain the polymorphic L1.Table 1 Primers and probes used in this study
Primer/Probe Name
5’ L1Hs Primer
5’ L1Hs Probe (Chr 15)
5’ L1Hs Probe (other loci tested)




5’ Chr4 esv3475 Locus Primer
5’ Chr4 esv4912 Locus Primer
3’ L1Hs Primer
3’ L1Hs Probe
3’ Chr15 AC216176 Locus Primer
3’ Chr4 esv3475 Locus Primer
3’ Chr4 esv4912 Locus PrimerPartitioning of template DNA in ddPCR not only affords
a reduction of this nonspecific background due to tem-
plate dilution, it also allows an accurate determination of
the concentration of the polymorphic L1 of interest in
the input DNA. In this report, we apply ddPCR technol-
ogy to the detection of rare L1 elements, allowing detec-
tion levels as low as one in every 10,000 cells. Our
ddPCR assays incorporate L1 primers and probes that
are common to each 5’ or 3’ junction ddPCR and specif-
ically detect the youngest, actively mobile, L1Hs subfa-
miliy. By using universal L1 5’- and 3’-end primers and
probes, paired with locus-specific flanking primers, this
L1 detection method will prove useful as a way to rap-
idly identify de novo L1 insertion events in a heteroge-
neous tumor sample and to quantitate their frequency
within an individual tumor sample. Additionally, L1
ddPCR allows heterozygote and homozygote loci to be
easily distinguished through parallel detection of a sec-
ond genomic locus.
Results
For validation or discovery of de novo L1 insertion events,
we designed assays to detect either the 5’- or 3’-insertion
junctions at specific genomic loci. The core of each assay
is a single primer and probe specific to the youngest L1
subfamily, L1Hs [2]. One primer and probe set is located
at the 3’ end of L1Hs (Table 1; 3’ L1Hs primer, 3’ L1Hs
probe), which may be used to detect both full-length and
truncated L1Hs elements when paired with an appro-
priate locus-specific primer (Figure 1). The other pri-
mer and probe set is located at the 5’ end of L1Hs
(Table 1; 5’ L1Hs primer, 5’ L1Hs probe) to detect full-
length L1Hs 5’-insertion junctions when paired with an
appropriate locus-specific primer (Figure 1). AmplificationSequence
5’ GGAAATGCAGAAATCACCGTCTTC 3’
5’ FAM AGGAACAGCTCCGGTCTACAGCTC BHQ1 3’












Figure 1 Schematic of L1Hs droplet digital PCR (ddPCR) assays.
(A) A 5’-FAM labeled Taqman™ probe specific to the 5’ UTR of L1Hs
is paired with an L1 5’ UTR-specific primer. The probe and primer
anneal to complementary DNA strands. This primer/probe set can be
used in conjunction with a unique genomic flanking primer to detect
the 5’-insertion junction of specific full-length L1 elements in the
human genome using ddPCR. A control assay using a primer and
5’-VIC labeled probe set specific to a housekeeping gene (RPP30) can
be used in parallel to determine copy number. (B) A 5’-FAM labeled
Taqman™ probe specific to the 3’ end of L1Hs is paired with an L1Hs-
specific primer. The probe and primer anneal to complementary DNA
strands. This primer/probe set can be used in conjunction with a
unique genomic flanking primer to detect the 3’ insertion junction of
specific L1Hs elements in the human genome using ddPCR.
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erates FAM fluorescence through nucleolytic cleavage of
the annealed L1Hs-specific probe by Taq polymerase. For
each experiment, a threshold of fluorescence is set relative
to negative controls to measure the quantity of droplets
that do or do not contain template target DNA. Through
separation of DNA templates for PCR in up to 20,000
droplets and measurement of fluorescence for each drop-
let at the terminal plateau phase of PCR, ddPCR-based L1
detection is capable of a high degree of discrimination that
is not possible with standard TaqMan™ assays [14]. Add-
itionally, L1 ddPCR assays can be multiplexed with control
ddPCR assays for housekeeping genes such as RPP30 to
allow for accurate copy number determination [20].
Because they exist in high genomic copy number, L1
elements can contribute to significant background signal
in PCR-based assays. In our assay designs, the L1Hs 5’
and 3’ end probes anneal to the same DNA strand as the
locus-specific primer in each assay to ensure fluorescent
signal is generated by extension of the primer at the L1-
occupied chromosomal locus (Figure 1). This minimizes
fluorescent signal arising from linear extensions off
primers annealed at the numerous other genomic L1
loci. There is, however, still the possibility of amplifica-
tion of two inverted L1Hs elements by two L1-specific
primers resulting in background fluorescence in negative
samples.
We were able to generate L1-specific primers and
probes that target young L1 insertions and result inonly a minimal degree of non-specific background
(Table 1, Figures 2 and 3). We developed a ddPCR assay
for the L1 5’ end to detect de novo full-length L1 insertion
events. Using a known polymorphic full-length L1Hs on
Chromosome 15 (AC216176; [21]) as a model for our
assay, we were able to successfully design a ddPCR assay
that is able to robustly detect a specific L1Hs 5’-insertion
junction known to be homozygous for the polymorphic L1
element in the cell line tested (Figure 2). To determine the
limit of sensitivity of our ddPCR assay, we performed ten-
fold dilutions of this sample as a mixture with DNA from a
sample known to be negative for the insertion, thus keep-
ing the total input genomic DNA constant for each ddPCR.
Detection of RPP30 by VIC fluorescence is consistent in
each dilution experiment. This analysis allowed us to deter-
mine that the limit of sensitivity of our assay is as low as
one positive cell in 10,000 total cells (0.01%) (Figure 2).
To assay specific 3’-insertion junctions of polymorphic
L1 elements by ddPCR, we designed primers and probes
unique to the 3’ end of the youngest L1Hs subfamily,
which constitute the vast majority of L1 elements cap-
able of retrotransposition [2]. The 3’ end of the 3’ L1Hs
primer makes use of an AC dinucleotide at position
5926 of L1Hs, which gives the primer specificity to only
these youngest L1 elements. Thus, although the primer
can probably anneal to a significant portion of genomic L1
elements, it will only be able to prime DNA synthesis from
these actively mobile, and therefore most interesting, L1
elements. Additionally, the L1 3’-end probe makes use of a
G nucleotide at position 6011 of L1Hs, making it also spe-
cific for only the youngest L1 elements [2,22,23].
For the 3’ junction ddPCR experiment, we investigated
the same known polymorphic full-length L1Hs on Chro-
mosome 15 used as a model for our 5’-junction assay
(AC216176; [21]). Using this primer and probe set, we
were able to robustly detect a single, specific L1 3’-inser-
tion junction with only minimal background (Figure 3).
We additionally performed a dilution experiment as de-
scribed above and were able to detect the L1 3’-insertion
junction to one positive cell in every 1,000 total cells
(0.1%) (Figures 3 and 4). Because establishment of the
polymorphic L1 detection limit was our goal in these ex-
periments, this ddPCR did not include RPP30 detection.
Additionally, we showed that the 3’ end L1 primer and
probe sets are specific to young L1 elements, as they do
not amplify a known older (L1PA4) genomic L1 (data not
shown).
To show that the L1-specific primers and probes may be
used to detect the 5’- and 3’-insertion junctions of multiple
polymorphic loci, locus specific primers were designed to
detect the 5’ and 3’ junctions of two other known poly-
morphic full-length L1Hs elements (Additional file 1:
Figure S1, Additional file 2: Figure S2, Additional file 3:
Figure S3, Additional file 4: Figure S4, Additional file 5:
Figure 2 Detection of chromosome 15 AC216176 L1Hs by the 5’ junction droplet digital PCR (ddPCR) assay. Each panel represents a
single ddPCR experiment whereby a DNA sample (defined below) is segregated into individual droplets and assessed for the presence of the L1
locus (FAM) and RPP30 locus (VIC) using two different fluorophores in Taqman™ assays (see Figure 1). The FAM and VIC fluorescence for each
droplet is plotted as a data point on each graph. FAM fluorescent signal (Channel 1) is plotted on the y-axis and VIC fluorescent signal (Channel
2) is plotted on the x-axis. The droplet threshold for each fluorophore used is indicated by the magenta lines, determining whether a droplet is
considered positive or negative for either FAM or VIC fluorescence. The positive or negative fluorescence assessment for each quadrant is labeled
accordingly for the plot describing the experiment with 100% GM01632 DNA. The blue dots represent individual droplets that contain at least
one copy of the L1 locus tested but not the RPP30 locus (FAM positive, VIC negative), the green dots represent droplets that contain at least one
copy of the RPP30 gene and not the L1 locus (VIC positive, FAM negative), and the orange dots represent droplets that contain at least one copy
of both the RPP30 gene DNA and the L1 locus tested (positive for both FAM and VIC). We tested 160 ng of BsaJI-digested genomic DNA from
GM01632 cells, which are homozygous for the polymorphic L1 element (100%), and tenfold dilutions of this same sample as a mixture with BsaJI-
digested genomic DNA from GM01631 cells, which do not have this polymorphic L1 insertion (10%-0.01%), thus keeping the total input genomic
DNA constant for each ddPCR. Additionally, as a negative control, 160 ng of BsaJI-digested genomic DNA from GM01631 cells was tested (0%).
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Figure S7, Additional file 8: Figure S8). Detection of both
5’- and 3’-insertion junctions for a polymorphic element on
Chromosome 4 (Database of Genomic Variants ID: esv
3475, [24,25]) was sensitive to one positive cell in 1,000
total cells (0.1%) (Additional file 1: Figure S1, Additional file
2: Figure S2, Additional file 3: Figure S3, Additional file 4:
Figure S4). Likewise, detection of both 5’- and 3’-insertion
junctions of another polymorphic element on Chromosome
4 (Database of Genomic Variants ID: esv4912, [24,25]) was
sensitive to one positive cell in 1,000 total cells (0.1%)(Additional file 5: Figure S5, Additional file 6: Figure S6,
Additional file 7: Figure S7, Additional file 8: Figure S8).
Discussion
Recent advances in detection of de novo L1 integration
events by HTS have resulted in an increased under-
standing of the potential role L1 elements might play in
the development of tumors. To date, L1 insertions have
been detected by HTS in five different cancer types, and
many of these insertions have been fully validated by
traditional PCR-based strategies [6-11]. There are many
Figure 3 Detection of chromosome 15 AC216176 L1Hs by the 3’ junction ddPCR assay. The L1Hs 3’ junction ddPCR assay uses a L1-specific
primer, L1-specific 5’-FAM labeled Taqman™ probe, and a locus-specific primer near the Chromosome 15 AC216176 3’-insertion junction, as shown
in Figure 1B. The FAM fluorescent signal (Ch 1) for each droplet is plotted on the y-axis for each of the ddPCR experiments, which are separated
by a dotted yellow line, with input DNA indicated above each experiment. Each droplet is cumulatively counted as an ‘Event Number’ for the
ddPCR experiments analyzed in tandem, and plotted along the x-axis. The positive droplet fluorescence threshold is indicated by the magenta
line, which determines whether a droplet is considered positive or negative for FAM fluorescence. Thus, the blue dots represent individual
droplets that contain at least one copy of the L1 locus tested. We tested 200 ng of BamHI-digested genomic DNA from HeLa cells, which contain
the polymorphic L1 element, and tenfold dilutions of this same sample as a mixture with BamHI-digested genomic DNA from HEK293 cells, which do
not have this polymorphic L1 insertion. Percentages given reflect the amount of input DNA with 100% corresponding to 200 ng of DNA. This assay
robustly detects the 3’-insertion junction of the polymorphic full-length AC216176 L1Hs element when present in the genomic DNA from a cell line
positive for that polymorphism (HeLa 100%), but not in a cell line negative for that polymorphism (HEK293 100%). L1-positive droplets are observed at
dilutions as low as 0.01% of the DNA with this assay.
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tected through the use of HTS, but have not been able
to be successfully validated. One likely explanation for
this discrepancy is the genomic heterogeneity associated
with tumors.
HTS technology has afforded researchers the ability to
identify extremely low-frequency events that are difficult
to validate by traditional PCR-based methods due to a
high rate of background signal. De novo L1 insertions in
tumors can often be classified as low-frequency events
for a number of reasons. First, it is often difficult to fully
separate normal adjacent tissue from tumors, with tissue
dissected from certain tumor types sometimes contain-
ing a greater fraction normal than cancerous tissue [26].
Second, the timing of L1 mobilization in tumors has not
been fully established. If L1 insertions occur at late
stages in the development of a tumor, they will only be
represented in a small fraction of the cells that composethe tumor. In this case, it remains very likely that such
de novo L1 insertion events would be detected by some
HTS studies, but would not necessarily be detectable by
traditional PCR.
Droplet digital PCR (ddPCR) has proven itself capable
of detecting extremely low frequency events [27]. In this
study, we report the ability of a ddPCR assay to detect
an L1 insertion event in as few as 0.01% to 0.1% of cells.
This assay has a minimal level of background signal,
which is surprising given the prolific nature of the L1
template in the human genome. The most likely source
of background signal is the high level of L1Hs 3’ ends
(approximately 5000 matching the 3’ L1Hs primer, but
500,000 with a partial match), resulting in off-target
amplification between two L1-specific primers. Regardless
of this, we are able to robustly detect an L1-positive signal
in a low fraction of cells. Our ddPCR assay is not only a
robust, straightforward tool to validate L1 insertion events
Figure 4 Concentration plot of chromosome 15 AC216176 L1Hs by the 3’ junction droplet digital PCR (ddPCR) assay. The input DNA
concentrations in copies/μl (Ch1 Conc) for the ddPCR experiments described in Figure 3 were calculated by the QuantaSoft Analysis Software.
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tifying the fraction of cells in the tumor, or other material,
that have that particular insertion.
Tumor cells undergo constant evolution and produce
subclonal populations of cells, each containing different
signatures of genomic rearrangements [28]. These chromo-
somal aberrations may serve as biomarkers for minor sub-
clonal populations that harbor the capacity for relapse [28].
Indeed, there is a major effort to use HTS data to describe
the subclonal genomic constituency of tumors and identify
biomarkers for invasive subclonal populations of cells
[29,30]. In addition to the validation of unique L1 inser-
tions identified by HTS of tumors, the assays described
here may be used to track and quantify mosaic L1 loci
used as biomarkers for subclonal populations of cancer
cells and, if an L1 insertion is unique to an individual’s
identified cancer, establish a minimum level of residual
disease detection.
Detection of rare alleles in the human population such
as single-nucleotide polymorphisms, small insertions or
deletions, or mobile element polymorphisms allows de-
termination of disease-causing candidate genomic loci
through association studies and shows regions of our
genome that have been subject to selective pressures
[31,32]. Establishment of rare allele frequencies through
individual genotyping is a laborious and expensive
process that can be overcome through methods that in-
terrogate pools of human genomic DNA [33,34]. Our
assay may be used as a means of establishing rare allele
frequencies, in the range of 0.01%, in pools of human
genomic DNA. Detection of the rare BRAF V600E allele
has been previously demonstrated by ddPCR [14].Conclusions
Retrotransposition of long interspersed element 1 (L1)
in human germline and somatic cells contributes to gen-
omic variation in human populations and is implicated
in tumorigenesis. In this study, we designed droplet
digital PCR (ddPCR) assays to detect rare L1 insertion
events in heterogeneous human genomic DNA samples.
Traditional qPCR methods are unable to confidently dis-
cern rare target DNA sequences among input DNA as
complex as a human genome due to low-chance priming
events that cause background signal and lead to false-
positive determinations. This effect is exacerbated when
the target DNA involves L1 sequence, which occupies
approximately 17% of the human genome. Using univer-
sal 5’ and 3’ L1 primers and probes in ddPCR, paired
with a locus-specific primer near the assayed insertion
site, we detected polymorphic L1 5’ and 3’ junctions in
genomic DNA from a heterogeneous sample when as
few as 0.01% of the cells contained the polymorphic L1.
The ability to confidently detect and simultaneously
quantify the level of a L1 insertion locus in a mosaic
sample, such as tumor biopsy genomic DNA, will allow
rapid validation of high-throughput sequencing data on
de novo L1 insertions for a given sample, establishment
of a minimum of residual disease detection for a cancer
cell-specific L1 insertion, or sampling of pools of human
genomic DNA for rare L1 allele detection.
Methods
Selection of L1 loci and primer/probe design
Polymorphic L1 elements were detected from genomic
DNA from fibroblast cell lines GM01630, GM01631 and
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Sequencing Identification and Mapping of Primed L1 El-
ements (SIMPLE) (VAS, unpublished data). These poly-
morphic elements were previously confirmed by PCR.
An identified polymorphic L1Hs locus was selected on
the basis of identity to the L1Hs consensus sequence: a
Chromosome 15 full-length L1Hs locus (AC216176;
[21]). Additional polymorphic L1 loci tested were chosen
among previously characterized polymorphic full-length
L1 elements on Chromosome 4 (Database of Genomic
Variants ID: esv4912, esv3475 [24,25]), and were assayed
on the basis of identity to the L1Hs consensus sequence.
Probes and primers were designed to match either the 5’
or 3’ end of the L1Hs consensus sequence (Table 1). The
L1Hs 3’ primer and probe incorporate diagnostic nucle-
otides specific to L1Hs that are not present in older L1
elements. These L1Hs-specific primer/probe sets can
be paired with a unique flanking primer specific to the
genomic region of interest for detection of the 5’- and
3’-insertions junctions. Primers and probes were syn-
thesized by Integrated DNA Technologies (Coralville,
IA, USA), with the exception of those used for detection
of RPP30 (Applied Biosystems now Life Technologies;
Grand Island, NY, USA) (Table 1).
Droplet digital PCR reaction conditions
Genomic DNA from fibroblast cell lines was extracted using
the DNEasy Blood and Tissue Kit (Qiagen; Germantown,
MD, USA). The 5’ junction ddPCR assays were performed
in 20-μL reactions using ddPCR Supermix for Probes
(Bio-Rad; Hercules, CA, USA) and 150 to 200 ng of BsaJI-
or BamHI-digested input DNA. Restriction enzyme diges-
tions were done according to manufacturers’ protocol
(New England BioLabs; Ipswitch, MA, USA). In the 5’
junction ddPCR assays, 900 nM 5’ L1Hs primer, 900 nM
locus-specific primer, and 250 nM 5’ L1Hs probe was
used. The 5’ junction ddPCR assays for the Chromosome
15 AC216176 locus included detection of the housekeep-
ing gene RPP30 with 900 nM of each RPP30-specific pri-
mer and 250 nM RPP30 probe. Because the two loci are
not linked, each droplet has a probability of being positive
for either one of the loci, and some droplets will be either
negative or positive for both. The relationship between
presence/absence of each locus in a droplet is defined by
the Poisson distribution and allows robust, digital quantifi-
cation of the two loci relative to one another. Droplet
generation was performed as per the manufacturer’s in-
structions. Cycling conditions were 95°C for 10 min,
followed by 40 cycles of 94°C for 30 seconds and 64°C for
two minutes, and then a final 10-min incubation at 98°C.
Droplet reading was performed on a QX100 ddPCR drop-
let reader (Bio-Rad; Hercules, CA, USA) for the Chromo-
some 15 AC216176 locus, a QX200 ddPCR droplet reader
(Bio-Rad; Hercules, CA, USA) for the other loci testedand analysis was done using QuantaSoft Analysis software
(Bio-Rad; Hercules, CA, USA).
The 3’ junction ddPCR assays were performed in 20-μL
reactions using ddPCR Supermix for Probes (No dUTP)
(Bio-Rad; Hercules, CA, USA) and 200 ng BamHI-digested
input DNA. In the 3’ junction ddPCR assay of the Chromo-
some 4 esv4912 polymorphic L1, 900nM of 3’ L1Hs primer,
900nM of locus-specific primer, and 200nM of 3’ L1Hs
probe was used. In all other 3’ junction ddPCR assays,
900nM of 3’ L1Hs primer, 4.5 μM of locus-specific primer,
and 200nM of 3’ L1Hs probe was used. Droplet generation
was performed as per the manufacturer’s instructions.
Cycling conditions were 95°C for 10 min, followed by
40 cycles of 94°C for 30 seconds and 64°C for one mi-
nute, and then a final 10-min incubation at 98°C. Drop-
let reading was performed on a QX200 ddPCR droplet
reader (Bio-Rad; Hercules, CA, USA), and analysis was
done using QuantaSoft Analysis software (Bio-Rad;
Hercules, CA, USA).
Genomic DNA from the following cell lines was used:
GM01630, GM01631 and GM01632 (Coriell Institute;
Camden, NJ, USA), Flp-In-293 (denoted HEK293 in figures
and figure legends, the parental line of these cells; Invitro-
gen now Life Technologies; Grand Island, NY, USA), HeLa
(American Type Culture Collection; Manassas, VA,
USA, item number: CCL-2), LoVo (American Type
Culture Collection; Manassas, VA, USA, item number:
CCL-229), HCT116D (HCT116 derivative with a Flp-In
site integrated kindly provided by J. Issa [35]; denoted
HCT116 in figures and figure legends).Droplet digital PCR mixing experiments
For mixing experiments, cell line genomic DNA positive
for a particular L1 insertion was mixed via tenfold dilutions
with cell line genomic DNA negative for that particular L1
insertion. Following mixing, dilutions were added at 150 ng
to 200 ng per ddPCR reaction as described above.
Additional files
Additional file 1: Figure S1. Detection of Chromosome 4 esv3475
L1Hs by the 5’ junction ddPCR assay. The L1Hs 5’ junction ddPCR assay
uses a L1-specific primer, L1-specific 5’-FAM labeled Taqman™ probe, and
a locus-specific primer near the Chromosome 4 esv3475 5’-insertion
junction, as shown in Figure 1A. The FAM fluorescent signal (Ch 1) for
each droplet is plotted on the y-axis for each ddPCR experiment, which
are separated by a dotted yellow line and indicated above each experi-
ment with the input DNA. Each droplet is cumulatively counted as an
“Event Number” for the ddPCR experiments analyzed in tandem, and
plotted along the x-axis. The positive droplet fluorescence threshold for each
fluorophore used is indicated by the magenta line, which determines
whether a droplet is considered positive or negative for FAM fluorescence.
Thus, the blue dots represent individual droplets that contain at least one
copy of the L1 locus tested. We tested 200 ng of BamHI-digested genomic
DNA from LoVo cells, which contain the polymorphic L1 element, and
White et al. Mobile DNA  (2014) 5:30 Page 8 of 9tenfold dilutions of this same sample as a mixture with BamHI-digested
genomic DNA from HEK293 cells, which do not have this polymorphic L1
insertion, thus keeping the input genomic DNA constant for each ddPCR.
Percentages given reflect the amount of input DNA with 100% corresponding
to 200 ng of DNA. This assay robustly detects the 5’-insertion junction of the
polymorphic full-length esv3475 L1Hs element when present in the
genomic DNA from a cell line positive for that polymorphism (LoVo
100%), but not in a cell line negative for that polymorphism (HEK293
100%). L1-positive droplets are observed at dilutions as low as 0.1% of
the DNA for this locus.
Additional file 2: Figure S2. Concentration plot of Chromosome 4
esv3475 L1Hs by the 5’ junction ddPCR assay. The input DNA concentrations
in copies/μl (Ch1 Conc) for the ddPCR experiments described in Additional
file 1: Figure S1 were calculated by the QuantaSoft Analysis Software.
Additional file 3: Figure S3. Detection of Chromosome 4 esv3475
L1Hs by the 3’ junction ddPCR assay. The L1Hs 3’ junction ddPCR assay
used a L1-specific primer, L1-specific 5’-FAM labeled Taqman™ probe, and a
locus-specific primer near the Chromosome 4 esv3475 3’-insertion junction,
as shown in Figure 1B. The FAM fluorescent signal (Ch 1) for each droplet is
plotted on the y-axis for each ddPCR experiment, which are separated by a
dotted yellow line and indicated above each experiment with the input
DNA. Each droplet is cumulatively counted as an “Event Number” for the
ddPCR experiments analyzed in tandem, and plotted along the x-axis. The
positive droplet fluorescence threshold is indicated by the magenta line,
which determines whether a droplet is considered positive or negative for
FAM fluorescence. Thus, the blue dots represent individual droplets that
contain at least one copy of the L1 locus tested. We tested 200 ng of
BamHI-digested genomic DNA from LoVo cells, which contain the
polymorphic L1 element, and ten-fold dilutions of this same sample as a
mixture with BamHI-digested genomic DNA from HEK293 cells, which
do not have this polymorphic L1 insertion. Percentages given reflect
the amount of input DNA with 100% corresponding to 200 ng of DNA.
The positive droplet fluorescence threshold is indicated by the magenta
line. This assay robustly detects the 3’-insertion junction of the
polymorphic full-length esv3475 L1Hs element when present in the
genomic DNA from a cell line positive for that polymorphism (LoVo
100%), but not in a cell line negative for that polymorphism (HEK293
100%). L1-positive droplets are observed at dilutions as low as 0.1% of
the DNA for this locus.
Additional file 4: Figure S4. Concentration plot of Chromosome 4
esv3475 L1Hs by the 3’ junction ddPCR assay. The input DNA
concentrations in copies/ μl (Ch1 Conc) for the ddPCR experiments
described in Additional file 3: Figure S3 were calculated by the
QuantaSoft Analysis Software.
Additional file 5: Figure S5. Detection of Chromosome 4 esv4912
L1Hs by the 5’ junction ddPCR assay. Experiments were performed as in
Additional file 1: Figure S1 to determine the limit of detection for the 5’
junction of the polymorphic full-length esv4912 L1Hs element on
Chromosome 4 in a cell line positive for that polymorphism (HCT116
100%), in indicated experiments as an input mixture with genomic DNA
from a cell line negative for that polymorphism (HeLa).
Additional file 6: Figure S6. Concentration plot of Chromosome 4
esv4912 L1Hs by the 5’ junction ddPCR assay. The input DNA
concentrations in copies/μl (Ch1 Conc) for the ddPCR experiments
described in Additional file 5: Figure S5 were calculated by the
QuantaSoft Analysis Software.
Additional file 7: Figure S7. Detection of Chromosome 4 esv4912
L1Hs by the 3’ junction ddPCR assay. Experiments were performed as in
Additional file 3: Figure S3 to determine the limit of detection for the 3’
junction of the polymorphic full-length esv4912 L1Hs element on
Chromosome 4 in a cell line positive for that polymorphism (HCT116
100%), in indicated experiments as an input mixture with genomic DNA
from a cell line negative for that polymorphism (HeLa).
Additional file 8: Figure S8. Concentration plot of Chromosome 4
esv4912 L1Hs by the 3’ junction ddPCR assay. The input DNA
concentrations in copies/μl (Ch1 Conc) for the ddPCR experiments
described in Additional file 7: Figure S7 were calculated by the
QuantaSoft Analysis Software.Abbreviations
ddPCR: droplet digital PCR; HTS: high-throughput sequencing; L1: long
interspersed element 1; qPCR: quantitative PCR; TPRT: target primed reverse
transcription.
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